Early Post-Marketing Pharmacovigilance of BLASTOFERON®: An Interferon Beta 1a Biosimilar
Michael Kauffman(Roche (Switzerland)), Eva González(Hospital de Cruces), A. M. Vidal, Mariana Papouchado(Sab Biotherapeutics (United States)), H. Ferro, Aída Sterin‐Prync(Sab Biotherapeutics (United States)), Roberto A. Díez(Universidad de Buenos Aires)
Cited by 2
Related Papers
The Phagosome Proteome
|The Journal of Cell Biology|2001|692
RACK1 Competes with HSP90 for Binding to HIF-1α and Is Required for O2-Independent and HSP90 Inhibitor-Induced Degradation of HIF-1α
|Molecular Cell|2007|470
Selective inhibitors of nuclear export show that CRM1/XPO1 is a target in chronic lymphocytic leukemia
|Blood|2012|300